BA
PACB icon

Boston Advisors’s Pacific Biosciences PACB Stock Holding History

Boston Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-53,183
Closed -$278K – 588
2013
Q4 		$278K Buy
53,183
+27,859
+110% +$128K 0.01% 489
2013
Q3 		$140K Buy
+25,324
New +$87.9K 0.01% 551

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Boston Advisors's PACB Position: Q1 2014 in Review

Boston Advisors sold out of Pacific Biosciences (PACB) in Q1 2014, closing a stake of 53,183 shares — an estimated $278K sold.

Boston Advisors first reported a position in PACB in Q3 2013 and held it in 2 quarters. The position peaked at $278K in Q4 2013. 88 funds tracked by Wall St. Rank hold PACB as of Q1 2014.

  • Boston Advisors reported no remaining Pacific Biosciences position as of Q1 2014 after selling out during the quarter.
  • Boston Advisors sold 53,183 Pacific Biosciences shares in Q1 2014, an estimated $278K.
  • Boston Advisors first reported a position in Pacific Biosciences in Q3 2013 and held it in 2 quarters.
  • Boston Advisors's Pacific Biosciences position peaked at $278K in Q4 2013.
  • 88 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2014.

Based on Boston Advisors's 13F filing for Q1 2014, filed 23 Apr 2014.